Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia Arthur Gomes Oliveira Braga; Katia Borgia Barbosa Pagnano; Marina Dal'Bó Pelegrini Campioni; Ana Beatriz Pascoal Lopes; Gislaine Oliveira Duarte; Konradin Metze; Irene Lorand-Metze;

Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells Lena Avinery; Danielle Regev; Hazem Khamaisi; Jacob Gopas; Jamal Mahajna;

GLYCEMIC CONTROL, RENAL FUNCTION, AND HEMATOLOGICAL PARAMETERS: A RETROSPECTIVE REAL-WORLD ANALYSIS Melike Saday Bozkurt; Ali Turunç;